The European Commission has approved AstraZeneca’s (NYSE:AZN) Qtrilmet (metformin hydrochloride saxagliptin and dapagliflozin) modified-release tablets to improve glycemic control in adults with type 2 diabetes (T2D).
It was approved in the U.S. in May under the brand name Qternment XR.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.